Format

Send to

Choose Destination
Gut. 2018 Mar;67(3):473-484. doi: 10.1136/gutjnl-2016-312794. Epub 2016 Nov 7.

Protein and glycomic plasma markers for early detection of adenoma and colon cancer.

Author information

1
Translational Research Program, Public Health Sciences Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
2
Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
3
School of Public Health, University of Washington, Seattle, Washington, USA17.
4
Centre for Public Health Research, Massey University, Wellington, New Zealand.
5
University of Tennessee Health Science Center, Memphis, Tennessee, USA.
6
Moffitt Cancer Center, Tampa, Florida, USA.
7
Wako Life Sciences, Inc., Mountain View, California, USA.
8
Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan.
9
Great Lakes New England (GLNE) Clinical Validation Center of EDRN, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
10
VA Medical Center, Ann Arbor, Michigan, USA.
11
Department of Clinical Cancer Prevention, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Abstract

OBJECTIVE:

To discover and confirm blood-based colon cancer early-detection markers.

DESIGN:

We created a high-density antibody microarray to detect differences in protein levels in plasma from individuals diagnosed with colon cancer <3 years after blood was drawn (ie, prediagnostic) and cancer-free, matched controls. Potential markers were tested on plasma samples from people diagnosed with adenoma or cancer, compared with controls. Components of an optimal 5-marker panel were tested via immunoblotting using a third sample set, Luminex assay in a large fourth sample set and immunohistochemistry (IHC) on tissue microarrays.

RESULTS:

In the prediagnostic samples, we found 78 significantly (t-test) increased proteins, 32 of which were confirmed in the diagnostic samples. From these 32, optimal 4-marker panels of BAG family molecular chaperone regulator 4 (BAG4), interleukin-6 receptor subunit beta (IL6ST), von Willebrand factor (VWF) and CD44 or epidermal growth factor receptor (EGFR) were established. Each panel member and the panels also showed increases in the diagnostic adenoma and cancer samples in independent third and fourth sample sets via immunoblot and Luminex, respectively. IHC results showed increased levels of BAG4, IL6ST and CD44 in adenoma and cancer tissues. Inclusion of EGFR and CD44 sialyl Lewis-A and Lewis-X content increased the panel performance. The protein/glycoprotein panel was statistically significantly higher in colon cancer samples, characterised by a range of area under the curves from 0.90 (95% CI 0.82 to 0.98) to 0.86 (95% CI 0.83 to 0.88), for the larger second and fourth sets, respectively.

CONCLUSIONS:

A panel including BAG4, IL6ST, VWF, EGFR and CD44 protein/glycomics performed well for detection of early stages of colon cancer and should be further examined in larger studies.

KEYWORDS:

COLORECTAL ADENOMAS; COLORECTAL CANCER; COLORECTAL CANCER SCREENING; TUMOUR MARKERS

PMID:
27821646
PMCID:
PMC5420499
DOI:
10.1136/gutjnl-2016-312794
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Competing interests: Fred Hutchinson Cancer Research Center has filed patent applications on the results of this study. HY is an employee of Wako Life Sciences, Inc.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center